TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00152191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur)
Description: uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide, methotrexate, and fluorouracil
Description: cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
Study: NCT01580657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detailed baseline interview, enhanced HIV intervention
Description: Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General baseline interview, enhanced HIV intervention
Description: Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No baseline interview, enhanced HIV intervention
Description: This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Detailed baseline interview, standard of care intervention
Description: Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General baseline interview, standard of care intervention
Description: Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No baseline interview, standard of care intervention
Description: Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
Study: NCT05790148

Intervention type: DEVICE
Group type: OTHER
Intervention: 3Shape
Description: original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
Study: NCT04375995

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Impulse oscillometry
Description: Impulse oscillometry test will be applied to all groups.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Impulse oscillometry
Description: Impulse oscillometry test will be applied to all groups.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometric pulmonary function test
Description: Spirometric pulmonary function test will be applied to all groups.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometric pulmonary function test
Description: Spirometric pulmonary function test will be applied to all groups.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional exhaled nitric oxide (FENO) test
Description: FeNO test will be applied to asthma group.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thorax Computed Tomography
Description: Thorax Computed Tomography will be taken to the asthma group.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood eosinophil level
Description: The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.

Intervention type: OTHER
Group type: OTHER
Intervention: Asthma control test
Description: Asthma control test questions will be applied to the asthma group.

Intervention type: OTHER
Group type: OTHER
Intervention: Asthma quality of life scale
Description: Asthma quality of life scale (AQLQ) will be applied to the asthma group.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest X Ray
Description: Chest X Ray will be applied to the healthy control group.
Study: NCT01671982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tenofovir Dose Adjustment
Description: In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
Study: NCT00462891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IT System
Study: NCT03937661

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Autologous PFP intra ovarian infusion
Study: NCT01006395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: yearly infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: yearly infusion
Study: NCT03360994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WATChmAN Active Surveillance
Description: WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Active Surveillance
Description: In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
Study: NCT02057445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBV CTL's
Description: Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral Blood Donor
Description: Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
Study: NCT03974165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal-legume product 1
Description: The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal-legume product 2
Description: The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product
Description: The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference food
Description: The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
Study: NCT00021060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT00300274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Corticosteroids standard dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: Corticosteroids standard dose.
Study: NCT01421914

Intervention type: OTHER
Group type: OTHER
Intervention: Bupivacaine 0,5%
Description: The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
Study: NCT01213329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
Study: NCT02284191

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT Coronary Angiogram
Description: Completion of a CT Coronary Angiogram
Study: NCT03670368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
Study: NCT03051191

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
Study: NCT03670368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison group - written materials
Description: Written materials from the mentoring sessions will be provided to those in the comparison group
Study: NCT00021060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT01130467

Intervention type: DRUG
Intervention: methylphenidate
Description: IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
Study: NCT03051191

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA
Description: micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
Study: NCT01448616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Gel
Description: Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints.
Study: NCT00021060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01448616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Vaginal Gel
Description: Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints.
Study: NCT00608595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
Study: NCT01448616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal TFV Gel
Description: Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
Study: NCT04004078

Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.

Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
Study: NCT04204824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound and exercise
Description: The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound and exercise
Description: The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home
Study: NCT04641832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soccer heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
Study: NCT03139448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen via nasal cannula
Description: Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen via SuperNO2VA nasal mask
Description: The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
Study: NCT00392015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA
Description: Malaria Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
Description: Malaria Vaccines
Study: NCT00645112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: oral suspension, 7 mg/kg every 12 hours for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
Study: NCT03796910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 for SAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 for MAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
Study: NCT03796910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
Study: NCT02727270

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study
Study: NCT00608595

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: not noted
Study: NCT02727270

Intervention type: OTHER
Intervention: No Intervention - Observational Study
Description: No Intervention - Observational Study
Study: NCT00228306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise
Description: Rehab therapy is delivered for 8 weeks.